I think we need to make physicians who treat chronic myeloid leukemia treat the disease ... (TKIs), the standard-of-care therapy for CML. This can affect patients’ ability to continue with ...

Panelists discuss how advanced practice providers (APPs) implement effective monitoring strategies for patients with chronic myeloid leukemia (CML), including regular check-ins after starting new ...

17, 2024 — According to new research, 80% of patients with previously untreated or relapsed/refractory advanced-phase chronic myeloid leukemia (CML) -- including both accelerated or myeloid ...

Search for other works by this author on: ...

Georgia Cancer Center, Augusta, GA.

Hyderabad: Aurobindo Pharma Limited has announced that its wholly owned subsidiary, Eugia PharmaSpecialities Limited, has ...

The up move in the stock came after the company arm Eugia Pharma Specialities, received final approval from USFDA to ...

Aurobindo Pharma's shares rose nearly 3% after its subsidiary, Eugia Pharma, received USFDA approval to market Dasatinib ...

Dasatinib Tablets US market size was approximately $1.8 billion for the 12 months ended February 2025, based on industry data ...

Aurobindo Pharma Limited is pleased to announce that its wholly owned subsidiary, Eugia Pharma Specialities Limited, has ...

Enliven Therapeutics is a clinical-stage concern that has two candidates in its pipeline targeting oncology indications.